Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results
BA Nock, A Kaloudi, E Lymperis, A Giarika… - Journal of Nuclear …, 2017 - Soc Nuclear Med
We recently introduced the potent gastrin-releasing peptide receptor (GRPR) antagonist 68
Ga-SB3 ( 68 Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-…
Ga-SB3 ( 68 Ga-DOTA-p-aminomethylaniline-diglycolic acid-DPhe-Gln-Trp-Ala-Val-Gly-His-…
[HTML][HTML] NeoBOMB1, a GRPR-Antagonist for Breast Cancer Theragnostics: First Results of a Preclinical Study with [67Ga]NeoBOMB1 in T-47D Cells and Tumor …
A Kaloudi, E Lymperis, A Giarika, S Dalm, F Orlandi… - Molecules, 2017 - mdpi.com
Background: The GRPR-antagonist-based radioligands [ 67/68 Ga/ 111 In/ 177 Lu]NeoBOMB1
have shown excellent theragnostic profiles in preclinical prostate cancer models, while [ …
have shown excellent theragnostic profiles in preclinical prostate cancer models, while [ …
Radiometal-dependent biological profile of the radiolabeled gastrin-releasing peptide receptor antagonist SB3 in cancer theranostics: Metabolic and biodistribution …
E Lymperis, A Kaloudi, W Sallegger… - Bioconjugate …, 2018 - ACS Publications
Recent advances in oncology involve the use of diagnostic/therapeutic radionuclide-carrier
pairs that target cancer cells, offering exciting opportunities for personalized patient treatment…
pairs that target cancer cells, offering exciting opportunities for personalized patient treatment…
Improving the In Vivo Profile of Minigastrin Radiotracers: A Comparative Study Involving the Neutral Endopeptidase Inhibitor Phosphoramidon
A Kaloudi, BA Nock, E Lymperis… - Cancer Biotherapy …, 2016 - liebertpub.com
Minigastrin radiotracers, such as [ 111 In-DOTA]MG0 ([ 111 In-DOTA-DGlu 1 ]minigastrin),
have been considered for diagnostic imaging and radionuclide therapy of CCK2R-positive …
have been considered for diagnostic imaging and radionuclide therapy of CCK2R-positive …
[HTML][HTML] Impact of clinically tested NEP/ACE inhibitors on tumor uptake of [111In-DOTA]MG11—first estimates for clinical translation
A Kaloudi, BA Nock, E Lymperis, R Valkema… - EJNMMI research, 2016 - Springer
Background We have recently shown that treatment of mice with the neutral endopeptidase (NEP)
inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of …
inhibitor phosphoramidon (PA) improves the bioavailability and tumor uptake of …
Comparative evaluation of the new GRPR‐antagonist 111In‐SB9 and 111In‐AMBA in prostate cancer models: Implications of in vivo stability
E Lymperis, A Kaloudi, P Kanellopoulos… - Journal of Labelled …, 2019 - Wiley Online Library
Gastrin‐releasing peptide receptors (GRPRs) are overexpressed in prostate cancer,
representing attractive targets for diagnosis and therapy with bombesin (BBN)‐like radioligands. …
representing attractive targets for diagnosis and therapy with bombesin (BBN)‐like radioligands. …
99mTc-labeled gastrins of varying peptide chain length: Distinct impact of NEP/ACE-inhibition on stability and tumor uptake in mice
A Kaloudi, BA Nock, E Lymperis, EP Krenning… - Nuclear Medicine and …, 2016 - Elsevier
Introduction In situ inhibition of neutral endopeptidase (NEP) has been recently shown to
impressively increase the bioavailability and tumor uptake of biodegradable gastrin …
impressively increase the bioavailability and tumor uptake of biodegradable gastrin …
In vivo inhibition of neutral endopeptidase enhances the diagnostic potential of truncated gastrin 111In-radioligands
A Kaloudi, BA Nock, E Lymperis, W Sallegger… - Nuclear Medicine and …, 2015 - Elsevier
Introduction Radiolabeled gastrin analogs represent attractive candidates for diagnosis and
therapy of cholecystokinin subtype-2 receptor (CCK2R)-expressing tumors. Radiolabeled …
therapy of cholecystokinin subtype-2 receptor (CCK2R)-expressing tumors. Radiolabeled …
[HTML][HTML] Comparing Gly11/dAla11-Replacement vs. the in-Situ Neprilysin-Inhibition Approach on the Tumor-targeting Efficacy of the 111In-SB3/111In-SB4 …
E Lymperis, A Kaloudi, P Kanellopoulos, M de Jong… - Molecules, 2019 - mdpi.com
Background: The GRPR-antagonist 68 Ga-SB3 visualized prostate cancer lesions in animal
models and in patients. Switching radiometal from 68 Ga to 111 In impaired tumor targeting …
models and in patients. Switching radiometal from 68 Ga to 111 In impaired tumor targeting …
[HTML][HTML] Localization of 99mTc-GRP Analogs in GRPR-Expressing Tumors: Effects of Peptide Length and Neprilysin Inhibition on Biological Responses
A Kaloudi, E Lymperis, P Kanellopoulos, B Waser… - Pharmaceuticals, 2019 - mdpi.com
The overexpression of gastrin-releasing peptide receptors (GRPRs) in frequently occurring
human tumors has provided the opportunity to use bombesin (BBN) analogs as radionuclide …
human tumors has provided the opportunity to use bombesin (BBN) analogs as radionuclide …